2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis

Lisa Ehlers, Johan Askling, Hans W.J. Bijlsma, Maria Cinta Cid, Maurizio Cutolo, Bhaskar Dasgupta, Christian Dejaco, William G. Dixon, Nils Feltelius, Axel Finckh, Kate Gilbert, Sarah Louise Mackie, Alfred Mahr, Eric Lawrence Matteson, Lorna Neill, Carlo Salvarani, Wolfgang A. Schmidt, Anja Strangfeld, Ronald F. Van Vollenhoven, Frank Buttgereit

Research output: Contribution to journalArticle

Abstract

Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis and is frequently associated with comorbidities related to the disease itself or induced by the treatment. Systematically collected data on disease course, treatment and outcomes of GCA remain scarce. The aim of this EULAR Task Force was to identify a core set of items which can easily be collected by experienced clinicians, in order to facilitate collaborative research into the course and outcomes of GCA. A multidisciplinary EULAR task force group of 20 experts including rheumatologists, internists, epidemiologists and patient representatives was assembled. During a 1-day meeting, breakout groups discussed items from a previously compiled collection of parameters describing GCA status and disease course. Feedback from breakout groups was further discussed. Final consensus was achieved by means of several rounds of email discussions after the meeting. A three-round Delphi survey was conducted to determine a core set of parameters including the level of agreement. 117 parameters were regarded as relevant. Potential items were subdivided into the following categories: General, demographics, GCA-related signs and symptoms, other medical conditions and treatment. Possible instruments and assessment intervals were proposed for documentation of each item. To facilitate implementation of the recommendations in clinical care and clinical research, a minimum core set of 50 parameters was agreed. This proposed core set intends to ensure that relevant items from different GCA registries and databases can be compared for the dual purposes of facilitating clinical research and improving clinical care.

Original languageEnglish (US)
JournalAnnals of the rheumatic diseases
DOIs
StatePublished - Jan 1 2019

Fingerprint

Giant Cell Arteritis
Research
Electronic mail
Advisory Committees
Feedback
Patient Advocacy
Systemic Vasculitis
Documentation
Signs and Symptoms
Registries
Datasets
Comorbidity
Demography
Databases
Therapeutics

Keywords

  • Adverse Events, Antirheumatic Agents
  • methods, Giant Cell Arteritis, Glucocorticoids, Polymyalgia Rheumatica, Registries, Rheumatic Disease and Risk, Treatment Outcome
  • therapeutic use, Biomedical Research

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. / Ehlers, Lisa; Askling, Johan; Bijlsma, Hans W.J.; Cid, Maria Cinta; Cutolo, Maurizio; Dasgupta, Bhaskar; Dejaco, Christian; Dixon, William G.; Feltelius, Nils; Finckh, Axel; Gilbert, Kate; Mackie, Sarah Louise; Mahr, Alfred; Matteson, Eric Lawrence; Neill, Lorna; Salvarani, Carlo; Schmidt, Wolfgang A.; Strangfeld, Anja; Van Vollenhoven, Ronald F.; Buttgereit, Frank.

In: Annals of the rheumatic diseases, 01.01.2019.

Research output: Contribution to journalArticle

Ehlers, L, Askling, J, Bijlsma, HWJ, Cid, MC, Cutolo, M, Dasgupta, B, Dejaco, C, Dixon, WG, Feltelius, N, Finckh, A, Gilbert, K, Mackie, SL, Mahr, A, Matteson, EL, Neill, L, Salvarani, C, Schmidt, WA, Strangfeld, A, Van Vollenhoven, RF & Buttgereit, F 2019, '2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis', Annals of the rheumatic diseases. https://doi.org/10.1136/annrheumdis-2018-214755
Ehlers, Lisa ; Askling, Johan ; Bijlsma, Hans W.J. ; Cid, Maria Cinta ; Cutolo, Maurizio ; Dasgupta, Bhaskar ; Dejaco, Christian ; Dixon, William G. ; Feltelius, Nils ; Finckh, Axel ; Gilbert, Kate ; Mackie, Sarah Louise ; Mahr, Alfred ; Matteson, Eric Lawrence ; Neill, Lorna ; Salvarani, Carlo ; Schmidt, Wolfgang A. ; Strangfeld, Anja ; Van Vollenhoven, Ronald F. ; Buttgereit, Frank. / 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. In: Annals of the rheumatic diseases. 2019.
@article{d8bec3f3a7a34365869686a3dfa5ed26,
title = "2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis",
abstract = "Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis and is frequently associated with comorbidities related to the disease itself or induced by the treatment. Systematically collected data on disease course, treatment and outcomes of GCA remain scarce. The aim of this EULAR Task Force was to identify a core set of items which can easily be collected by experienced clinicians, in order to facilitate collaborative research into the course and outcomes of GCA. A multidisciplinary EULAR task force group of 20 experts including rheumatologists, internists, epidemiologists and patient representatives was assembled. During a 1-day meeting, breakout groups discussed items from a previously compiled collection of parameters describing GCA status and disease course. Feedback from breakout groups was further discussed. Final consensus was achieved by means of several rounds of email discussions after the meeting. A three-round Delphi survey was conducted to determine a core set of parameters including the level of agreement. 117 parameters were regarded as relevant. Potential items were subdivided into the following categories: General, demographics, GCA-related signs and symptoms, other medical conditions and treatment. Possible instruments and assessment intervals were proposed for documentation of each item. To facilitate implementation of the recommendations in clinical care and clinical research, a minimum core set of 50 parameters was agreed. This proposed core set intends to ensure that relevant items from different GCA registries and databases can be compared for the dual purposes of facilitating clinical research and improving clinical care.",
keywords = "Adverse Events, Antirheumatic Agents, methods, Giant Cell Arteritis, Glucocorticoids, Polymyalgia Rheumatica, Registries, Rheumatic Disease and Risk, Treatment Outcome, therapeutic use, Biomedical Research",
author = "Lisa Ehlers and Johan Askling and Bijlsma, {Hans W.J.} and Cid, {Maria Cinta} and Maurizio Cutolo and Bhaskar Dasgupta and Christian Dejaco and Dixon, {William G.} and Nils Feltelius and Axel Finckh and Kate Gilbert and Mackie, {Sarah Louise} and Alfred Mahr and Matteson, {Eric Lawrence} and Lorna Neill and Carlo Salvarani and Schmidt, {Wolfgang A.} and Anja Strangfeld and {Van Vollenhoven}, {Ronald F.} and Frank Buttgereit",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/annrheumdis-2018-214755",
language = "English (US)",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis

AU - Ehlers, Lisa

AU - Askling, Johan

AU - Bijlsma, Hans W.J.

AU - Cid, Maria Cinta

AU - Cutolo, Maurizio

AU - Dasgupta, Bhaskar

AU - Dejaco, Christian

AU - Dixon, William G.

AU - Feltelius, Nils

AU - Finckh, Axel

AU - Gilbert, Kate

AU - Mackie, Sarah Louise

AU - Mahr, Alfred

AU - Matteson, Eric Lawrence

AU - Neill, Lorna

AU - Salvarani, Carlo

AU - Schmidt, Wolfgang A.

AU - Strangfeld, Anja

AU - Van Vollenhoven, Ronald F.

AU - Buttgereit, Frank

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis and is frequently associated with comorbidities related to the disease itself or induced by the treatment. Systematically collected data on disease course, treatment and outcomes of GCA remain scarce. The aim of this EULAR Task Force was to identify a core set of items which can easily be collected by experienced clinicians, in order to facilitate collaborative research into the course and outcomes of GCA. A multidisciplinary EULAR task force group of 20 experts including rheumatologists, internists, epidemiologists and patient representatives was assembled. During a 1-day meeting, breakout groups discussed items from a previously compiled collection of parameters describing GCA status and disease course. Feedback from breakout groups was further discussed. Final consensus was achieved by means of several rounds of email discussions after the meeting. A three-round Delphi survey was conducted to determine a core set of parameters including the level of agreement. 117 parameters were regarded as relevant. Potential items were subdivided into the following categories: General, demographics, GCA-related signs and symptoms, other medical conditions and treatment. Possible instruments and assessment intervals were proposed for documentation of each item. To facilitate implementation of the recommendations in clinical care and clinical research, a minimum core set of 50 parameters was agreed. This proposed core set intends to ensure that relevant items from different GCA registries and databases can be compared for the dual purposes of facilitating clinical research and improving clinical care.

AB - Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis and is frequently associated with comorbidities related to the disease itself or induced by the treatment. Systematically collected data on disease course, treatment and outcomes of GCA remain scarce. The aim of this EULAR Task Force was to identify a core set of items which can easily be collected by experienced clinicians, in order to facilitate collaborative research into the course and outcomes of GCA. A multidisciplinary EULAR task force group of 20 experts including rheumatologists, internists, epidemiologists and patient representatives was assembled. During a 1-day meeting, breakout groups discussed items from a previously compiled collection of parameters describing GCA status and disease course. Feedback from breakout groups was further discussed. Final consensus was achieved by means of several rounds of email discussions after the meeting. A three-round Delphi survey was conducted to determine a core set of parameters including the level of agreement. 117 parameters were regarded as relevant. Potential items were subdivided into the following categories: General, demographics, GCA-related signs and symptoms, other medical conditions and treatment. Possible instruments and assessment intervals were proposed for documentation of each item. To facilitate implementation of the recommendations in clinical care and clinical research, a minimum core set of 50 parameters was agreed. This proposed core set intends to ensure that relevant items from different GCA registries and databases can be compared for the dual purposes of facilitating clinical research and improving clinical care.

KW - Adverse Events, Antirheumatic Agents

KW - methods, Giant Cell Arteritis, Glucocorticoids, Polymyalgia Rheumatica, Registries, Rheumatic Disease and Risk, Treatment Outcome

KW - therapeutic use, Biomedical Research

UR - http://www.scopus.com/inward/record.url?scp=85063293236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063293236&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2018-214755

DO - 10.1136/annrheumdis-2018-214755

M3 - Article

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -